EDIL3 Activators
EDIL3 Activators encompass a range of chemical compounds that indirectly amplify the functional activity of EDIL3, predominantly through their influence on cell adhesion and migration pathways. Roscovitine, by targeting cyclin-dependent kinases, particularly CDK2, modulates cell cycle progression, which in turn, can accentuate the role of EDIL3 in cell adhesion and migration. Similarly, LY294002 and Wortmannin, both PI3K inhibitors, curtail Akt phosphorylation, a pivotal regulator in various cellular functions, thereby potentially intensifying EDIL3's involvement in these processes. Inhibitors of the MAPK pathway, such as SB203580 and PD98059, which target p38 MAPK and MEK respectively, shift cellular signaling dynamics, thus potentially fortifying EDIL3's contribution to cell-matrix interactions and angiogenesis. The alteration of these pathways by these inhibitors hints at an enhanced functional role for EDIL3 in related cellular processes.
Further, Dasatinib and Imatinib, both tyrosine kinase inhibitors, influence cell adhesion and migration through their action on Src family kinases, Bcr-Abl, and c-Kit, offering a potential upsurge in EDIL3-mediated processes in these areas. U0126, another MEK inhibitor, along with SP600125, a JNK pathway modulator, also contribute to the enhancement of EDIL3's function by influencing key signaling pathways involved in cell stress responses and inflammation, which are critical to EDIL3's role. Rapamycin and Sorafenib, targeting mTOR and multiple kinases including VEGFR and PDGFR respectively, present a broader spectrum of pathway modulation, indirectly enhancing the functional activity of EDIL3 in cell growth, proliferation, and angiogenesis. Erlotinib, by inhibiting EGFR, plays a similar role, potentially bolstering EDIL3's involvement in key cellular functions. Collectively, these EDIL3 Activators, through their targeted effects on a multitude of signaling pathways, facilitate the enhancement of EDIL3-mediated functions in cell adhesion, migration, and angiogenesis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine, a cyclin-dependent kinase inhibitor, indirectly enhances EDIL3 activity by inhibiting CDK2, which is involved in cell cycle regulation. This inhibition can lead to altered cell adhesion and migration processes, thereby enhancing EDIL3's role in these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, by reducing PI3K activity, indirectly enhances EDIL3 function in cell adhesion and migration. The inhibition of PI3K leads to a decrease in Akt phosphorylation, a process that regulates various cellular functions including those associated with EDIL3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly enhances EDIL3 function by inhibiting p38 MAPK, which is involved in inflammatory responses and stress-activated pathways. This alteration in signaling pathways can enhance EDIL3's role in cell-matrix interactions and angiogenesis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, an inhibitor of MEK, indirectly enhances EDIL3's function by modulating the MAPK/ERK pathway. This modulation can lead to changes in cellular adhesion and migration, processes in which EDIL3 is involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, another PI3K inhibitor, enhances EDIL3 activity by inhibiting PI3K, thus affecting downstream Akt signaling. This inhibition can lead to alterations in cell adhesion and migration, where EDIL3 plays a significant role. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, indirectly enhances EDIL3 function by inhibiting Src family kinases and Bcr-Abl. This inhibition can affect cell adhesion and migration, thus potentially enhancing the role of EDIL3 in these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, an inhibitor of JNK, can enhance EDIL3's role in cell adhesion and migration by modulating the JNK pathway, which is involved in various cellular processes including inflammation and stress response. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly enhances EDIL3 function by inhibiting the mTOR pathway, which is involved in cell growth and proliferation. This inhibition can affect cell adhesion and migration processes where EDIL3 is active. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multikinase inhibitor, enhances EDIL3's function by inhibiting multiple kinases including VEGFR and PDGFR. This inhibition can modulate cell adhesion and migration, enhancing the role of EDIL3 in these processes. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, an EGFR inhibitor, indirectly enhances EDIL3 activity by inhibiting EGFR, which can lead to alterations in cell adhesion and migration, processes in which EDIL3 is involved. | ||||||